A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia
Open Access
- 20 May 2009
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 20 (8) , 1397-1401
Abstract
Background: Smoking may affect the efficacy of chemotherapy and the incidence of adverse events. We investigated the correlation between smoking history and gemcitabine-induced neutropenia. Patients and methods: Data on smoking history and incidence of grade 3–4 neutropenia were retrospectively gathered for 103 chemo-naive patients treated with gemcitabine monotherapy (59 patients with pancreatic, 41 with hepatobiliary and three with other cancers). Results: There was a significantly higher incidence of grade 3–4 neutropenia among patients without a history of smoking (55.7%) than among those with a history of smoking (including current and ex-smokers; 23.6%) [odds ratio (OR) 0.244, 95% confidence interval (CI) 0.105–0.569; P < 0.001]. After adjustment for age, gender, platelet and baseline neutrophil counts, history of surgery for primary cancer, creatinine concentration, hemoglobin concentration, aspartate aminotransferase concentration, alanine aminotransferase concentration and total bilirubin concentration, logistic regression analysis identified a history of smoking as an independent inverse predictor of gemcitabine-induced neutropenia (OR 0.188, 95% CI 0.057–0.618; P = 0.006). Conclusion: Patients without a history of smoking may be at higher risk of developing gemcitabine-induced neutropenia. The mechanism underlying this phenomenon is unclear at this point.Keywords
Funding Information
- Smoking Research Foundation
This publication has 20 references indexed in Scilit:
- Cigarette Smoking and Irinotecan Treatment: Pharmacokinetic Interaction and Effects on NeutropeniaJournal of Clinical Oncology, 2007
- Pharmacokinetics of Gemcitabine in Japanese Cancer Patients: The Impact of a Cytidine Deaminase PolymorphismJournal of Clinical Oncology, 2007
- Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non–small cell lung cancerClinical Pharmacology & Therapeutics, 2006
- Cellular pharmacology of gemcitabineAnnals of Oncology, 2006
- Treatment of Inoperable and/or Metastatic Biliary Tree Carcinomas With Single-Agent Gemcitabine or in Combination With Levofolinic Acid and Infusional Fluorouracil: Results of a Multicenter Phase II StudyJournal of Clinical Oncology, 2001
- Phase I Trial of Gemcitabine in Patients with Advanced Pancreatic CancerJapanese Journal of Clinical Oncology, 2001
- Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III StudyJournal of Clinical Oncology, 2000
- Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2000
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancerAnnals of Oncology, 1996